MA23395A1 - Procede de preparation de nouvelles formulations - Google Patents

Procede de preparation de nouvelles formulations

Info

Publication number
MA23395A1
MA23395A1 MA23723A MA23723A MA23395A1 MA 23395 A1 MA23395 A1 MA 23395A1 MA 23723 A MA23723 A MA 23723A MA 23723 A MA23723 A MA 23723A MA 23395 A1 MA23395 A1 MA 23395A1
Authority
MA
Morocco
Prior art keywords
preparation
new formulations
formulations
new
Prior art date
Application number
MA23723A
Other languages
English (en)
Inventor
George Doughty David
Dutta Pathak Ram
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10746644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA23395(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MA23395A1 publication Critical patent/MA23395A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA23723A 1993-12-15 1994-12-13 Procede de preparation de nouvelles formulations MA23395A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939325644A GB9325644D0 (en) 1993-12-15 1993-12-15 Novel formulation

Publications (1)

Publication Number Publication Date
MA23395A1 true MA23395A1 (fr) 1995-07-01

Family

ID=10746644

Family Applications (1)

Application Number Title Priority Date Filing Date
MA23723A MA23395A1 (fr) 1993-12-15 1994-12-13 Procede de preparation de nouvelles formulations

Country Status (35)

Country Link
US (1) US6113944A (fr)
EP (1) EP0734260B2 (fr)
JP (1) JP3037757B2 (fr)
KR (1) KR100367796B1 (fr)
CN (1) CN1071116C (fr)
AP (1) AP540A (fr)
AT (1) ATE180973T1 (fr)
AU (1) AU697982B2 (fr)
BG (1) BG62755B1 (fr)
BR (1) BR9408219A (fr)
CA (4) CA2274389C (fr)
CZ (1) CZ287891B6 (fr)
DE (1) DE69419033T2 (fr)
DK (1) DK0734260T4 (fr)
DZ (1) DZ1835A1 (fr)
ES (1) ES2132610T5 (fr)
FI (1) FI962445L (fr)
GB (1) GB9325644D0 (fr)
GR (1) GR3031047T3 (fr)
HU (1) HUT75880A (fr)
IL (1) IL111978A (fr)
MA (1) MA23395A1 (fr)
MY (1) MY112123A (fr)
NO (1) NO307366B1 (fr)
NZ (1) NZ277790A (fr)
OA (1) OA10297A (fr)
PL (1) PL314980A1 (fr)
RO (1) RO115413B1 (fr)
RU (1) RU2146141C1 (fr)
SA (1) SA94150373B1 (fr)
SI (1) SI0734260T2 (fr)
SK (1) SK282620B6 (fr)
UA (1) UA42745C2 (fr)
WO (1) WO1995016448A1 (fr)
ZA (1) ZA949900B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086053A1 (en) * 1993-12-15 2002-07-04 Smithkline Beecham Plc Formulations, tablets of paroxetine and process to prepare them
SK283608B6 (sk) * 1995-02-06 2003-10-07 Smithkline Beecham Plc Bezvodý hydrochlorid paroxetínu, spôsob jeho výroby a použitie
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
AU3108097A (en) 1997-06-10 1998-12-30 Synthon B.V. 4-phenylpiperidine compounds
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
US6168805B1 (en) * 1998-05-07 2001-01-02 Endo Pharmaceuticals, Inc. Aqueous process for manufacturing paroxetine solid dispersions
GB9810181D0 (en) * 1998-05-13 1998-07-08 Smithkline Beecham Plc Novel formulations
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
AU5078700A (en) * 1999-06-22 2001-01-09 Smithkline Beecham Plc Novel composition
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
CA2418038A1 (fr) * 2000-08-28 2002-03-07 Synthon B.V. Compositions a base de paroxetine et leurs procedes de fabrication
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
BR0206164A (pt) 2001-07-31 2003-10-28 Lundbeck & Co As H Partìculas cristalinas de oxalato de escitalopram, método para a produção de partìculas cristalinas de oxalato de escitalopram, e, forma de dosagem unitária sólida
NZ532432A (en) * 2001-10-22 2005-02-25 Synthon Bv N-formyl paroxetine compounds and their use in a synthetic route for obtaining paroxetine
IL162666A0 (en) * 2001-12-28 2005-11-20 Teva Pharma A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
AU2005265174A1 (en) * 2004-06-23 2006-01-26 Merck & Co., Inc. Estrogen receptor modulators
WO2006018318A1 (fr) * 2004-08-18 2006-02-23 Synthon B.V. Compositions liquides de paroxetine
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
US20060216345A1 (en) * 2005-03-24 2006-09-28 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition including paroxetine
CA2629514A1 (fr) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Phenylpiperidines substituees a activite serotoninergique et proprietes therapeutiques ameliorees
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
CA2937365C (fr) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee
CN109771381B (zh) * 2017-11-13 2021-02-19 北京福元医药股份有限公司 一种帕罗西汀药物制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50116401A (fr) * 1974-03-04 1975-09-11
ZA813205B (en) † 1980-12-05 1983-03-30 Smith Kline French Lab Dosage units
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
EP0223334B1 (fr) * 1985-08-10 1991-07-10 Beecham Group Plc Procédé de préparation d'aryl-pipéridine-carbinols
EP0223403B1 (fr) * 1985-10-25 1993-08-04 Beecham Group Plc Dérivé de pipéridine, sa préparation et son utilisation comme médicament
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
KR930702000A (ko) * 1990-11-24 1993-09-08 데이빗 로버츠 노년기 치매, 식용항진, 편두통, 또는 식용불량의 치료를 위한 파로세틴의 사용
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders

Also Published As

Publication number Publication date
MY112123A (en) 2001-04-30
CA2214575A1 (fr) 1995-06-22
BG62755B1 (bg) 2000-07-31
EP0734260B1 (fr) 1999-06-09
NO962547D0 (no) 1996-06-14
EP0734260B2 (fr) 2008-07-09
FI962445A0 (fi) 1996-06-12
CA2178637C (fr) 1997-12-23
FI962445A7 (fi) 1996-06-12
EP0734260A1 (fr) 1996-10-02
BG100648A (bg) 1997-02-28
AU697982B2 (en) 1998-10-22
CA2274389C (fr) 2004-09-14
NO962547L (no) 1996-06-14
CN1137236A (zh) 1996-12-04
HU9601665D0 (en) 1996-08-28
DK0734260T4 (da) 2008-09-29
JPH09506602A (ja) 1997-06-30
CA2178637A1 (fr) 1995-06-22
HK1012285A1 (en) 1999-07-30
BR9408219A (pt) 1997-08-26
CA2214575C (fr) 1999-12-07
AP9400704A0 (en) 1995-01-31
SI0734260T1 (sl) 1999-08-31
KR100367796B1 (ko) 2003-07-22
IL111978A0 (en) 1995-03-15
IL111978A (en) 2000-07-16
HUT75880A (en) 1997-05-28
ES2132610T5 (es) 2008-12-16
CN1071116C (zh) 2001-09-19
RU2146141C1 (ru) 2000-03-10
SA94150373B1 (ar) 2006-05-27
AU1314595A (en) 1995-07-03
US6113944A (en) 2000-09-05
DE69419033T2 (de) 1999-11-25
GR3031047T3 (en) 1999-12-31
SA94150373A (ar) 2005-12-03
CZ287891B6 (cs) 2001-03-14
ZA949900B (en) 1995-10-10
NO307366B1 (no) 2000-03-27
RO115413B1 (ro) 2000-02-28
CA2274387A1 (fr) 1995-06-22
SI0734260T2 (sl) 2008-12-31
ES2132610T3 (es) 1999-08-16
GB9325644D0 (en) 1994-02-16
PL314980A1 (en) 1996-09-30
FI962445L (fi) 1996-06-12
ATE180973T1 (de) 1999-06-15
OA10297A (en) 1997-10-07
SK75696A3 (en) 1996-11-06
WO1995016448A1 (fr) 1995-06-22
DK0734260T3 (da) 1999-11-15
JP3037757B2 (ja) 2000-05-08
SK282620B6 (sk) 2002-10-08
DZ1835A1 (fr) 2002-02-17
CZ176396A3 (en) 1996-09-11
AP540A (en) 1996-09-20
NZ277790A (en) 1998-02-26
CA2274389A1 (fr) 1995-06-22
UA42745C2 (uk) 2001-11-15
DE69419033D1 (de) 1999-07-15

Similar Documents

Publication Publication Date Title
MA23395A1 (fr) Procede de preparation de nouvelles formulations
MA23143A1 (fr) Procede pour la preparation de compositions vaccinantes .
MA23850A1 (fr) Procede de preparation de compositions vaccinantes
MA23918A1 (fr) Procede de preparation de compositions vaccinantes
MA23814A1 (fr) Procede de preparation de compositions vaccinantes
MA22668A1 (fr) Procede de preparation d'oxamides .
FI914174A7 (fi) Menetelmä piperidyylialkyyliamiinien valmistamiseksi
FI945441A0 (fi) Uusi menetelmä 7beta-substituoitu-4-atsa-5alfa-androstan-3-onien valmistamiseksi
FI973281L (fi) Menetelmä tiettyjen atsasykloheksapeptidien valmistamiseksi
FR2722210B1 (fr) Nouvelles streptogramines et procede de preparation de streptogramines par mutasynthese
EP1023250A4 (fr) Procede de preparation de 2,6-dialkylnaphtalene
MA23663A1 (fr) Procede de preparation de formulations pharmaceutiques
ITMI931680A1 (it) Procedimento per la preparazione di alcansolfonammidi
FI933755A7 (fi) Menetelmä trans-piperidiini-2,5-dikarboksylaattien valmistamiseksi
FR2626883B1 (fr) Procede de preparation de n-phosphonomethyl-imino-diacetique
EP0823904A4 (fr) Procede de preparation de spiroindolines
FI913464A7 (fi) Menetelmä 1-hydroksimetyylipyratsolien valmistamiseksi
FI922125A7 (fi) Mikrobiologinen menetelmä 5-hydroksipyratsiinikarboksyylihapon valmistamiseksi
FR2643902B1 (fr) Procede de preparation de n-allylmetatrifluoromethylaniline
FI923866A7 (fi) Menetelmä 1-hydroksialkyyli-5-nitroimidatsolien valmistamiseksi
FR2728566B1 (fr) Procede de preparation de pentene-nitriles
FI953617A7 (fi) Menetelmä substituoitujen 4-hydroksikumariinien valmistamiseksi
FR2763942B1 (fr) Nouveau procede de preparation de n-acylaminoacides
FI930237A7 (fi) Menetelmä 4,6-dialkoksipyrimidiinien valmistamiseksi
FR2750998B1 (fr) Procede de preparation de k-carraghenase